Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study

MethodsTo be eligible for the study, patients had to have been taking Keppra((R)) as monotherapy or polytherapy for at least 6 months. Between March 2013 and April 2017, patients were invited to switch to Matever((R)) as part of their follow-up. We evaluated the number of seizures per month, drug-related adverse events and electroencephalography before the switch (T0, baseline) and 6 months after switching (T1). Furthermore, we reported the long-term follow-up of patients who continued to use Matever((R)) after the end of the study, considering the most recent visit for each patient (T2).

Background and purposeThe purpose of this study was to determine whether switching from branded levetiracetam (Keppra((R))) to a levetiracetam generic equivalent product (Matever((R))) in an epilepsy cohort could provide adequate results in terms of seizure control and tolerability.